Cambridge Nutranostics has developed a point-of-care prototype of OCCL test for testing blood plasma oxygen
PR95340
Cambridge Nutranostics has developed a point-of-care prototype of OCCL test for testing blood plasma oxygen to monitor health in post stroke and TIA patients for dementia prevention
CAMBRIDGE, England, April 6, 2022 /PRNewswire=KYODO JBN/--
Cambridge Nutranostics Ltd, CNL, http://occltest.com has begun validation in
clinic of its first test prototype to assess and monitor plasma oxygen, the
part of the total blood O2, which can cross the capillary wall and deliver this
essential gas for tissue cell respiration.
Medical researchers from Cambridge University, Papworth Hospital and led by Dr
Ivan Petyaev, published their discovery that extracellular lipids,
lipoproteins, can be the main oxygen carrier in blood plasma
https://pubmed.ncbi.nlm.nih.gov/9505864/. It was found that a decline in OCCL,
a reduction of oxygen supply to tissues, might contribute to depression of
their functions and development of tissue hypoxia.
CNL has now successfully completed conversion of the established laboratory
format OCCL test to its express dry chemistry based point-of-care diagnostic,
the first affordable test of its kind able to be used not only by any health
care practitioner but also by an untrained person at home. This test would
require only one drop of capillary blood and provide results within minutes.
One of the company's first marketing targets are people at risk of developing
dementia, and in particularly those who have already experienced hypoxic or
ischemic clinical events such as a stroke or a transient ischemic attack, TIA.
Around 78 million people globally and 1 person out of 5 of 65 years or older in
Japan will have dementia in 2030.
Stroke or TIA as an acute oxygen deprivation shock to the brain makes it more
vulnerable and susceptible for future cerebral hypoxia accompanying development
of the dementia. https://pubmed.ncbi.nlm.nih.gov/35072712/ Approximately 30% of
stroke patients go on to develop cognitive dysfunction within 3 years.
The OCCL point-of-care test would allow a health care practitioner or the
person himself or herself, to assess the level of plasma oxygen and detect its
potential changes, which may not have any other clinical manifestations. Early
diagnosis of these changes may trigger additional medical examination and allow
measures to be taken to improve tissue oxygenation.
The company is expecting to launch this test in the first half of 2023. Alexey
Shulepov, the CEO of CNL, says "the company is proud to develop this test to
help to prevent development of dementia and reduce its impact on people's lives
in every country".
dm@occltest.com
SOURCE: Cambridge Nutranostics
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。